NCT01923935View on ClinicalTrials.gov

Busulfan and Melphalan Conditioning in Multiple Myeloma

PHASE2UnknownINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

December 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

BUSULFEX®

BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)

DRUG

Alkeran®

Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)

Trial Locations (8)

410-769

RECRUITING

National Cancer Center, Goyang-si

405-760

NOT_YET_RECRUITING

Gachon University Gil Hospital, Namdong-gu

519-763

RECRUITING

Chonnam National University Hwasun Hospital, Hwasun-gun

135-710

NOT_YET_RECRUITING

Samsung Medical Center, Gangnam-gu

110-744

NOT_YET_RECRUITING

Seoul National University Hospital, Jongno-gu

158-710

NOT_YET_RECRUITING

Ewha Womans University Mokdong Hospital, Mokdong

137-701

NOT_YET_RECRUITING

Seoul St. Mary's hospital, Seocho-gu

120-752

NOT_YET_RECRUITING

Severance Hospital, Seodaemun-gu

Sponsors
All Listed Sponsors
collaborator

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Chonnam National University Hospital

OTHER